Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.45 |
| ▸ | NQO2 | P16083 | 5/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410267 | 1.00 | MTNR1A (0.46) | MTNR1AMTNR1BNQO2ACHETRPV1 | |
| SCHEMBL3410264 | 1.00 | MTNR1A (0.46) | MTNR1AMTNR1BNQO2ACHETRPV1 | |
| Hydrochloric Acid SCHEMBL7314463 | 0.99 | MTNR1A (0.45) | MTNR1AMTNR1BNQO2ACHETRPV1 | |
| SCHEMBL18989984 | 0.92 | MTNR1A (0.48) | MTNR1AMTNR1BNQO2 | |
| Hydrochloric Acid SCHEMBL7302239 | 0.86 | CYP11B1 (0.43) | MTNR1AMTNR1BNQO2ACHE | |
| SCHEMBL3411168 | 0.85 | TRPV1 (0.49) | MTNR1AMTNR1BNQO2ACHETRPV1 | |
| SCHEMBL3433701 | 0.85 | TRPV1 (0.49) | MTNR1AMTNR1BNQO2ACHETRPV1 | |
| SCHEMBL3411164 | 0.85 | TRPV1 (0.49) | MTNR1AMTNR1BNQO2ACHETRPV1 | |
| SCHEMBL3407321 | 0.83 | FFAR1 (0.43) | MTNR1AMTNR1BNQO2ACHE | |
| SCHEMBL8616324 | 0.82 | ACHE (0.46) | MTNR1AMTNR1BNQO2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | MTNR1A 673/4885MTNR1B 654/4885NQO2 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.